A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders
No Parkinson's-slowing drugs exist yet, but several promising candidates are advancing through trials with refined biomarker strategies.
This comprehensive systematic review of DMT development across Parkinsonian disorders finds no approved therapy to date, despite extensive trial activity including GLP-1 receptor agonists, alpha-synuclein antibodies, and kinase inhibitors. GLP-1 RAs have progressed to Phase 3 trials with mixed results, and the review calls for biomarker-driven trial stratification to improve success rates.
What the study was
- Study design
- Systematic review (literature search through May 2025)
- Population
- Patients with Parkinson's disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Clinical Pharmacology and Therapeutics
Why it surfaced
Comprehensive SR on Parkinson disease-modifying therapies covering GLP-1 RAs (watchlist) and broader neurodegeneration space. Field summary useful for pipeline context; no breakthrough results reported.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.